Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a total purchase price of $47.8 million. The company also reported its financial results for the third quarter and nine-months ended September 30, 2008.

"The turnaround at Nektar is now largely complete," said Nektar President and CEO Howard W. Robin. "We have created one of the most robust pipelines in biotech, dramatically improved the company's financial strength, assembled a new management team with a solid track record, and refocused the business around our powerful polymer and conjugate chemistry drug development platform."

Third Quarter 2008 Financial Results

Cash, cash equivalents, and short-term investments were $344.5 million at September 30, 2008 compared to $373.9 million at June 30, 2008.

Revenue for the three month period ended September 30, 2008 was $21.4 million compared to revenue of $56.3 million in the third quarter of 2007. For the first nine months of 2008, revenue was $61.8 million as compared to $207.3 million in the same period of 2007. This decrease in revenue is primarily the result of lower product manufacturing revenues due to the termination of the inhaled insulin collaboration by Pfizer in late 2007.

Nektar has continued to make significant improvements to its operating efficiencies as compared to a year ago. For the first nine months of 2008, the company's general and administrative expense was $37.0 million as compared to $42.3 million for the same period a year ago. Research and development expense was $109.1 million in the first nine months
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... among women using a newer method of planned sterilization ... over a 10-year period than using the more commonly ... University and UC Davis has found. , Published ... the study found the higher risk of pregnancy with ... Essure. , "This study provides essential information for ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... X-rays allowing, dentists to remineralize affected teeth. ... 3 /PRNewswire/ - Quantum Dental Technologies, a Canadian,diagnostic ... monitors the early onset of tooth decay without ... of invasive and painful procedures,and encourages better oral ...
... climate change places 1.7,billion people - 25% of ... warns,anti-poverty agency ActionAid., WASHINGTON, July 2 ... ActionAid launches a new report, "Cereal,Offenders: How the ... and What,They Can Do to Stop It." Read ...
... 2 Regarding the completely fabricated,item about GO3 ... July 14, 2008,edition of Star magazine, none of ... were contacted by the magazine prior to publication., ... reviewing its legal options and will vigorously pursue ...
... Jr,Washington Wizards Guard and Washington, DC native, will ... July 29 featuring bowling at Lucky Strike in,Chinatown. ... support the,cause, including Brendan Haywood and DeShawn Stevenson, ... Vince Carter, Kevin Durant, and,Chris Bosh. Additionally, Craig ...
... individual patients, study says , , WEDNESDAY, July 2 (HealthDay News) ... cells in the blood of lung cancer patients may make ... the genetic "signature" of particular tumors but to monitor changes ... think this is key to personalized medicine," said Dr. Daniel ...
... sports medicine specialist, John Albright, MD, will join three other physicians ... of Fame inductee. , ... Orlando, Florida (PRWEB) July ... MD, will join three other physicians as a 2008 American ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: